Afficher la couverture 'Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome | Mogenet, Alice' en grand format
/5

0 avis

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome

Archive ouverte

Mogenet, Alice | Barlesi, Fabrice | Besse, Benjamin | Michiels, Stefan | Karimi, Maryam | Tran-Dien, Alicia | Girard, Nicolas | Mazieres, Julien | Audigier-Valette, Clarisse | Locatelli-Sanchez, Myriam | Kamal, Maud | Gestraud, Pierre | Hamza, Abderaouf | Jacquet, Alexandra | Jimenez, Marta | Yara, Sabrina | Greillier, Laurent | Bertucci, François | Planchard, David | Soria, Jean-Charles | Bieche, Ivan | Tomasini, Pascale

Edité par CCSD ; Elsevier -

International audience. Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several mechanisms: genomic heterogeneity, blood-tumor barrier, and the brain-specific microenvironment. We conducted a study using data from the SAFIR02-LUNG trial. The primary objective was to compare the molecular profiles of non-small-cell lung cancer (NSCLC) with or without BMs. The secondary objective was to explore central nervous system (CNS) outcomes with various maintenance treatment regimens.

Suggestions

Du même auteur

Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial

Archive ouverte | Boyault, Sandrine | CCSD

International audience. Purpose: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized the approach to non-small cell lung cancer (NSCLC) treatment in the era of precision medicine. Their ...

Genomics to select treatment for patients with metastatic breast cancer

Archive ouverte | Andre, Fabrice | CCSD

International audience

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Archive ouverte | Derosa, Lisa | CCSD

International audience. Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documente...

Chargement des enrichissements...